127 related articles for article (PubMed ID: 21648223)
1. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Cohen MH; Farrell A; Justice R; Pazdur R
Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
[TBL] [Abstract][Full Text] [Related]
5. Imatinib: new indication. Efficacy in gastrointestinal stromal tumours must be confirmed.
Prescrire Int; 2003 Oct; 12(67):163-4. PubMed ID: 14610781
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
8. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
9. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
10. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
[TBL] [Abstract][Full Text] [Related]
11. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
Gronchi A; Blay JY; Trent JC
Cancer; 2010 Apr; 116(8):1847-58. PubMed ID: 20166214
[TBL] [Abstract][Full Text] [Related]
12. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of imatinib for treatment of metastatic GIST.
Patel S
Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
[TBL] [Abstract][Full Text] [Related]
19. Practical management of imatinib in gastrointestinal stromal tumors.
Barnes T; Reinke D
Clin J Oncol Nurs; 2011 Oct; 15(5):533-45. PubMed ID: 21951740
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
